1.95
-0.02(-1.02%)
Currency In USD
| Previous Close | 1.97 |
| Open | 1.98 |
| Day High | 2.04 |
| Day Low | 1.88 |
| 52-Week High | 2.66 |
| 52-Week Low | 0.86 |
| Volume | 408,583 |
| Average Volume | 327,625 |
| Market Cap | 118.12M |
| PE | -0.86 |
| EPS | -2.27 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 1.38 |
| Change | -0.02 |
If you invested $1000 in Acumen Pharmaceuticals, Inc. (ABOS) since IPO date, it would be worth $97.01 as of November 13, 2025 at a share price of $1.95. Whereas If you bought $1000 worth of Acumen Pharmaceuticals, Inc. (ABOS) shares 3 years ago, it would be worth $317.59 as of November 13, 2025 at a share price of $1.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβO
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
GlobeNewswire Inc.
Nov 05, 2025 9:00 PM GMT
NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers fo
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire Inc.
Aug 05, 2025 8:00 PM GMT
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers fo